Search

everythinglearnresearchcommunity

for

Search:↓

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.

Tofacitinib may help treat severe hair loss, but more research is needed.

Restoring hair bulb immune privilege is crucial for managing alopecia areata.

Alopecia areata treatment varies, with no optimal method established yet.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Activating the Wnt/β-catenin pathway could lead to new hair loss treatments.

The study found that diseases can be grouped by symptoms and that the accuracy of predicting disease-related genes varies with the data source.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

Treatment with plasma rich in growth factors improved hair density and thickness for hair loss patients.

Tiny needles with valproic acid can effectively regrow hair.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Advanced nanocarrier and microneedle drug delivery methods are more effective, safer, and less invasive for treating skin diseases.

Baricitinib is effective and safe for treating severe alopecia areata.

Topical JAK inhibitors may help treat some skin conditions but need more research.

Genetic screening is crucial for accurately diagnosing APS-1 due to its varied symptoms.

PPAR agonists show promise for skin conditions but need more research before being a main treatment.

PLGA-based microneedles are promising for safe and effective skin delivery of drugs and vaccines.

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

The document concludes that the skin's immune system is complex, involving interactions with hair follicles, nerves, and microbes, and can protect or cause disease, offering targets for new treatments.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

TGFβ's manipulation of inflammation and immune cells affects cancer spread, suggesting new treatment strategies and biomarkers.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

The document explains different types of hair loss, their causes, and treatments, and suggests future research areas.

Ginseng and its compounds may help hair growth and prevent hair loss, but more human trials are needed to confirm this.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Different treatments for alopecia areata have varying success rates and side effects; intralesional steroids are most effective.